Equillium, Inc. is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company focuses on advancing two preclinical product candidates: EQ504, an aryl hydrocarbon receptor modulator, and EQ302, an oral dual inhibitor of interleukin 15 and interleukin 21. Its goal is to become a fully integrated biotechnology firm that delivers life changing therapeutics for patients with unmet medical needs in gastroenterology dermatology and pulmonology.

Equillium, Inc. has not yet commercialized any product and therefore does not generate product sales revenue. The company finances its operations through private placements of equity and proceeds from securities purchase agreements. It also may pursue collaborations licensing agreements or grant funding in the future to support research and development activities.

Equillium, Inc. operates in a competitive biotechnology landscape where large pharmaceutical companies and specialized biotech firms pursue therapies for autoimmune and inflammatory diseases. The company differentiates itself through its novel mechanisms of action such as aryl hydrocarbon receptor modulation and dual interleukin inhibition. Its focus on oral delivery and tissue targeted approaches offers potential advantages over existing injectable biologics. While it faces competition from established players with greater resources its early stage pipeline and specific scientific expertise provide a distinct niche in the market.

Equillium, Inc. intends to serve patients suffering from severe autoimmune and inflammatory conditions such as ulcerative colitis celiac disease and related gastrointestinal disorders. Its future customers will include healthcare providers hospitals and clinics that prescribe and administer its therapies. The company also collaborates with research institutions and may partner with larger pharmaceutical firms for development and commercialization.